Abbott Laboratories's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings show how the company performed and help investors track business progress over time.
Earnings announcements reveal company profits, losses, and financial health that affect stock value.
Quarterly earnings show how the company performed and help investors track business progress over time.
Board additions and new equity programs affect company decision-making and employee incentives.
Legal settlements reduce future financial risk and can affect company finances and reputation.
Earnings announcements reveal company profits, losses, and financial health that affect stock value.
Major acquisitions expand company business, create new revenue streams, and impact future growth.
Stocky reads Abbott Laboratories's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Abbott Laboratories's most recent tracked filing was a 10-Q on 28 Jul 2026: Abbott reports second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.